Tag Archives: etfs

The Trouble With Momentum – And What To Do About It

Summary Growth stocks have outperformed value stocks in recent years, which is shining a spotlight on momentum. Unlike other investment factors, the momentum premium has been persistent since it was identified by financial academics in the 1990s. We believe that combining momentum with value and other factors within a multi-factor framework is a compelling way to address the challenge of tapping momentum profitably in a growth portfolio. It’s no secret that growth stocks have outperformed value stocks in recent years. For example, in the two years from September 1, 2013 to August 31, 2015, large cap growth stocks (as measured by the Russell 1000 Growth Index) returned 14.7% annualized vs. 9.6% annualized for value stocks (Russell 1000 Value Index). This pattern of outperformance has shone a spotlight on momentum , an investment factor that works particularly well in growth-stock investing. But making money by identifying growth stocks with momentum characteristics isn’t as easy as it sounds. In this column, I will explain why and briefly describe how Gerstein Fisher addresses some of the problems inherent in tilting a growth stock portfolio to momentum. Momentum: a Persistent Investment Factor First, let’s define what we mean by momentum. Momentum is the tendency for winning stocks (that is, stocks that have outperformed the market over the past three to 12 months) to keep winning and losing stocks to keep losing. First identified in papers co-authored in the early 1990s by Sheridan Titman, one of our Academic Partners, the momentum factor would seem to refute the weak form of the Efficient Market Hypothesis, which asserts that stock prices reflect all available information and that past price movements should be unrelated to future average returns. Momentum suggests that prior movements in price are in fact related to expected stock returns – that security prices essentially have memory, which students of statistics will recognize as serial correlation. Since those landmark studies in the 1990s, a number of other academic papers have established that a momentum strategy works not only in equity markets around the world (with the notable exception of Japan’s) but also in several other asset classes, including currencies and commodities. At Gerstein Fisher, we find that a momentum tilt works at least as well in our multi-factor real estate investment trust (aka REIT) portfolio as in our US and international growth equity strategies. Exhibit 1 shows the compound annualized returns from 1927 to 2014 for 10 portfolios formed on momentum (defined here as the one-year return skipping the most recent month). Investing in the highest past one-year return (i.e., highest-momentum) stocks generated a 16.9% annualized return, while the lowest decile of momentum lost 1.5% per year. Note the steady improvement in performance as momentum increases. (click to enlarge) Moreover, unlike some other investment factors identified by financial academics, momentum has remained remarkably robust and persistent. For instance, since the size premium for small cap stocks was identified in the early 1980s, it has shrunk dramatically (see my recent column for more on this phenomenon: ” Is the Small Cap Stock Premium Disappearing? “); similarly, the value premium has also sharply declined since Fama and French published their pioneering paper on it in 1992. Quite possibly, once seminal research is available in the public domain, quantitative investors target and thereby reduce the available premiums, although they still exist. But momentum seems to be different: our research shows that the strategy has remained profitable, generating a momentum premium of five to seven percentage points* even years after Prof. Titman’s groundbreaking papers in the 1990s. The Challenge for Momentum So if all of this academic and empirical evidence for momentum is present, then what’s the problem? For one thing, momentum stocks are also subject to short-term reversals, the tendency for stocks that have risen relative to the rest of the market in the last month to underperform those that have fallen relative to the rest of the market (for more on this topic, see our recently posted paper: ” Do past returns predict future returns? Evidence from Momentum and Short – Term Reversals “). In addition, the discipline and emotion-free decisions required to hold high-momentum winners and cut low-momentum losers every month are behaviorally difficult for many individual investors to make. Most importantly, there is a very large issue with turnover and transaction costs (and tax liabilities, if held in a taxable account) with a momentum growth stock portfolio. In short, without rules for controlling portfolio turnover, transaction costs will quickly devour a premium from a tilt to momentum (a monthly rebalanced, long-only momentum strategy may have a turnover of about 300%, implying a holding period of around four months). We believe that an effective approach to addressing the problem of excess turnover is by combining momentum, a so-called fast-moving factor, with value (which we may define, for instance, as a tilt to higher book-to-market stocks than the Russell 3000 Growth Index), a slow-moving factor. Combining these two negatively correlated factors in one portfolio provides factor diversification, which is a good thing since there are pronounced and different cycles to different factors. But we also find that by combining the signals of value and momentum, we can slow down portfolio trading dramatically and improve risk-adjusted performance, both relative to the index and compared to the sum of standalone value and momentum strategies-a typical advantage of a multi-factor strategy in one portfolio. We will soon publish our research on the optimum way to combine momentum and value in an academic journal. In the meantime, I invite you to read our working paper: ” Combining Value and Momentum “. Conclusion Growth stocks – and momentum – have been the source of strong performance in the stock market. The momentum premium is palpable but difficult to tap profitably in a growth portfolio. We believe that combining momentum with value and other factors within a multi-factor framework is a compelling way to address this challenge. *The momentum premium is defined as the returns of the highest 30% of large cap US stocks rated by momentum less the return of the lowest 30% of stocks rated by momentum. Data on momentum decile portfolios are taken from Ken French’s website. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Best 20+ Odds-On Oil And Gas E&P Stocks, As Seen By Fund Clients Of Market-Makers

Summary With Crude Oil Prices in mid $40s, up from high $30s, a turn may be coming for independent new extraction technology explorers and producers. Tough times of world price cuts by more than 60% leave only the strongly resourced, well-financed, advantaged survivors. Their rebound time may be near at hand, as seen in large-volume order flows from big-$ investment portfolio managers. Who are the best positioned energy stock survivors? The best candidates are indicated by the “order flow” from big-money “institutional” clients of market-making investment banks, suggesting high-probability additions to their billion-dollar portfolios. (If you have read this story before, please skip directly to Figures 1 and 2) The fund-management clients have extensive, experienced research staffs constantly looking for sound, long-term, rewarding investment candidates. The presence of their interest in these issues typically is a disruptive influence to markets because of their size of transaction orders. The “regular way” every-day “retail” investment transactions largely get handled (or mis-handled) by automated systems developed by advances in transaction technology. Those advances have cut the costs for individual investors to fractions of a cent per share, compared to pre-Y2K costs of sometimes a dollar or more a share. But big-volume “block” orders can’t be handled that way without crashing the system. They must be negotiated among other big players in this very serious game. That is where the market-maker firms play an important role. The MM firms know which players own what, and have a good idea of what their current appetites may be. Usually differences of opinion as to appropriate valuations for specific stocks are not evenly balanced enough among these fund-manager players to instantly “cross” trades of tens or hundreds of thousand shares. So the MM firms even out the balance between buyers and sellers by temporarily committing their own capital. But they don’t go naked. The at-risk commitments of MMs are always hedged in one way or another, and the cost of that protection is borne by the trade-originating client. It is built into the trade “spread” between the single per-share price of the block deal and the current “regular-way” market price. The cost of the hedge deal and the structure it takes is negotiated between the arbitrage artists of the MM firms block trade desks and “Prop” trade desks in open competitive combat. What it costs and the shape it takes reveals what these well-informed, profiting antagonists believe is possible to occur between now and the time it may take to unwind the contracts on derivatives used in the hedge. That often could be as much as a few months. So the range of possible prices implied is not an instantaneous, trivial spread. Often it is 10% to 20% or more, given the uncertainties involved in the underlying security. Where today’s market quote lies in that forecast range may be important in the stock’s future movement. The first thing to remember about this analysis is that it is a “snapshot” of current conditions, dominated by price relationships that are likely to change in coming days, weeks, and months. Those changes are typically the main point on most player scorecards. This article is not an evaluation of how “good” the companies involved are at managing, competing, profiting, or treating their employees or shareholders. It simply tells how well on this date the perceived prospects for each equity investment security candidate may be, compared with those of others, on a variety of matters and measures of concern. This is not a long-term hold evaluation. But it could identify overlooked, near-term value opportunities to be captured by active investing management. The place to start in the analysis is with the market character presented by each of the best dozens of stocks out of the hundred or more once on the scene. Figure 1 tells those stories: Figure 1 (click to enlarge) Source: Yahoo Finance, Peter Way Associates Items of concern here have to do with how easy it may be to get out of a position if in a hurry, and what the cost of doing so might entail. The first four columns do so by calculating how many market days’ average volume of trading at the current price it would take to completely replace existing shareholders. That is not expected to happen, it just gives a realistic comparative measure of how easy or difficult it might be to extricate oneself from an unwanted position. Extreme examples here are Enbridge (NYSE: ENB ), with a million-share-a-day trading volume to take over 3 years to clear its huge $34 billion of outstanding shares. At the other extreme is the market-tracking SPDR S&P 500 Index ETF (NYSEARCA: SPY ) with a five times as large ownership value, but 139 million share daily volume doing the task every 6 days. Yes, Sasol, Ltd.(NYSE: SSL ) shows a capital turn in over a thousand days, but it is a South African company and its principal share trading takes place in markets outside of the US. Another dimension of the distress of departure is what the typical trade cost may be, which can be indicated by the stock’s bid-offer spread. These days that tends to be a tiny fraction of the value per share during normal market hours. But every investor needs to protect themselves against errant or intentional malicious spread quotes by always using price limit orders when changing positions, instead of unrestrained “at market” orders. The other useful matter of perspective in Figure 1 is a sense of each stock’s current price in relation to its past year’s trading range, and a sense of how the size of that range compares to alternative investments. The Range Index [RI] tells what proportion of the whole range lies below the stock’s current price. A low past RI indicates a price depressed in comparison with earlier trading, and a high past RI tells of a stock that has been on the move up near new highs. The range size is a dimension only discussed in the media as an example of either triumph or disaster, but rarely in company of comparable alternatives. The average sizes here in this group are over 100%, meaning that a double in price (or a 50% drop) is commonplace. The latter phase just mentioned of that change scares most investors, as it should. But it is an all-too-common condition, often setting the stage for the former-mentioned next joy. So what does come next? That is what everyone wants to know, and not knowing for sure, everyone guesses at. MMs have a leg up in the game, since they know what their clients, with the money muscle to move markets, are trying to do. The well-informed protection sellers provide deals very likely to assure themselves of nice profits, with little likelihood of having to deliver on the immunization. A done deal tells where the extreme possibilities lie. Those outer limits have been shown in a high proportion of instances to be quite reachable. The agile, fleet-of-foot protection sellers usually manage to profitably transfer the accepted risks to others and get on to the next deal before having to make good on their bet this time (again). So the price range forecasts implied by the capital-risk hedging can be useful information to others interested in the stocks or ETFs involved. To determine how useful the current forecasts may be, we look back to how similar prior forecasts (made without knowledge of what next happened) were actually treated by a merciless marketplace. Figure 2 tells the particulars, and provides a means of ranking the attractiveness for wealth-building active investors. Figure 2 (click to enlarge) source: Peter Way Associates, blockdesk.com At the outset, something about Figure 2 should be understood. Columns (2) and (3) are current-day forecasts, implied by the self-protective actions of market-making professionals in the course of serving transaction orders from big-$ clients at or near column (4). All the remaining columns are matters of record of how prior forecasts for the subjects in column (1), made live in real-time over the past 5 years, have actually performed. Those prior forecasts were only those of the total available in (12) that had upside-to-downside proportions like the current forecast, described in (7). The Range Index [RI] tells what percentage of the whole forecast range lies below (4). The size of this sample set of forecasts has potential statistical implications if it is small. Few of the subjects of Figure 2 have that problem, and none of the top ten. This is the importance of column (12), a dimension pertinent to all references to prior performance. The number of forecasts available in any subject’s current situation is a function of the current Range Index. More will be available when the RI is in the 30-50 area and fewer when the subject is at extremes, nearing zero or 100. Market price behavior varies from subject to subject for a variety of reasons, so attractiveness based solely on RI can be misleading. That makes this kind of analysis in detail important. Additional evaluations may be useful when RIs are at or near extremes. The historical data of Figure 2 differs significantly from “back-test” data because it is based on the live forecasts made at the time, when subsequent price action confirmations were not available. The usual back-test data only is presented when full knowledge of the outcomes is at hand. That makes it impossible to know what kind of decisions might have been made at the time. This historical data applies our standard TERMD portfolio management discipline to buy positions of all column (12) sample forecasts. TERMD has been in existence for over a decade. It is more fully described below . For example, column (6) is an average of the worst-case price drawdowns from the closing price of the subject on the next market day after the forecast, over the holding period up to the position’s closing. This is the relevant measure of risk, since it identifies the greatest loss likely to be taken at the point of maximum emotional stress. Column (8) on the other hand, tells what proportion of the sample forecasts were able to recover from the (6) experience and be closed out profitably by reaching (5) sell targets or by TERMD’s holding period time limit of 3 months. Column (5) relates (2) to (4). Column (9) tells what the closeouts of all subject sample forecast positions averaged, profits, net of losses (by geometric mean). The CAGR of these experiences in (11) uses the average holding period of (10) in conjunction with (9). The promise of (5) is tested by (9) in (13). The proportion of (5) to (6) is shown in (14). Overall, a figure-of-merit is calculated in (15) by odds-weighting (5) by (8) and (6) by (8)’s complement, further conditioned by the frequency of (12). The table’s contents are ranked by (15). That ranking is what ordered Figure 1. What it all suggests Without getting into a detailed discussion of the attributes of interest, comparisons of the best-odds (most attractive by column 15) ten E&P stocks with a market-average tracking alternative ETF, SPY, show upside price changes (5) almost twice as large, and risk exposures (6) about one and a half times as large. Their forecast history translates into CAGR performances (11) four times as good as market results, with odds for profit outcomes (8) about the same, 8 out of every 10. But comparisons with the best 20 propositions from the measurable overall equity population of 2711 alternatives, puts the Oil&Gas E&P stocks at a disadvantage. The difference lies not in the size of the payoff promise, but in its follow-through. The average price gains of the population’s best stocks surpassed their forecasts +11.4% to +10.4% , with 9 out of every 10 experiences profitable, and average holding periods to reach payoffs shorter by 36 market days to 41, or roughly 7 weeks compared to 8. That leads to a CAGR past result (11) of 114%, double the comparable measure of +55% for the E&Ps. Conclusion I appears that there is sufficient early action in volume trade transactions in Oil & Gas independent Explorers and Producers to elevate expectations for their coming stock prices to a level more than competitive with passive market-index ETF investing. Best candidates may be PDC Energy (NASDAQ: PDCE ) and Matador Resources (NYSE: MTDR ). Perhaps in coming weeks this activity will strengthen and raise the prospects higher. But at present there are a number of alternative equity investments that substantially surpass the typical prospects of the best of this group. Commitments among those alternatives should be better rewarded. Patience, my energy friends. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Biotech ETFs In A Bull Market: Positioning For A Q4 Rally

Summary Biotech ETFs have rallied off a triple bottom. The XBI is still the leader up 22.64% YTD with a high turnover small cap portfolio. Position new buys with two complementary ETFs. Biotech ETF Trends: What to watch for in a 2015 bull market The biotech 15%+ correction and increased volatility has unnerved many investors and traders. Risk remains high due to macroeconomic concerns and recent weakness in the healthcare sector. Momentum is gone and many high-flying emerging stocks have been crushed. But the bull market is intact and since late last Friday buyers were coming into the favored stocks. The biotech sector is still the market leader. Large cap biopharmaceutical stocks have been hit and many are in the red and should recover, but they are too earnings dependent to make huge moves in Q4 so we favor mid and small caps for trading and new positions. Mid-caps are favored because many have strong pipelines with potential for clinical breakthroughs and M&A action. Stock picking will get harder so for re-balancing portfolios and new positions consider ETFs. It is very difficult to track or analyze ETF holdings except to note style i.e. large cap, small cap, diagnostics, services etc. If you believe we have bottomed in biotech for the year and that we are poised for the year-end rally, this could be a good time to accumulate positions. The action this week has been favorable but the technicals must hold in a sell-off. Healthcare has the best of both worlds in this market: growth from biotech/devices and stability from services and tools. Here is where we stand on major biotech ETFs: The First Trust NYSE Arca Biotechnology Index ETF ( FBT) 115.38 up 13.1% YTD, the iShares Nasdaq Biotechnology ETF ( IBB) 350.72 up 15.62% YTD, the SPDR Biotech ETF ( XBI) 228.67 up 22.64% YTD. Here is a summary of ETF trends to watch: The biotech sector is more dependent on healthcare economics so the Health Care Select Sect SPDR ETF (NYSEARCA: XLV ) needs to hold or move in tandem with biotech. XLV holdings include both biotech and large cap drugs: Johnson & Johnson ( JNJ), Pfizer Inc. ( PFE), Gilead Sciences, Inc. ( GILD), Merck & Co Inc. ( MRK), Amgen Inc. ( AMGN) etc. The small cap “equal weighted” XBI continues to be the leader although it can be more volatile particularly in down markets. The holdings include more speculative stocks that are turned over rapidly probably with a lot of help from algorithms: Anacor Pharmaceuticals, Inc. ( ANAC), Exelixis, Inc. ( EXEL), KYTHERA Biopharmaceuticals ( KYTH), Dynavax Technologies Corporation ( DVAX), Sarepta Therapeutics, Inc. ( SRPT) etc. IBB favors well known large caps among the top ten positions. Holdings include all the usual suspects adding up to 59% of total: Celgene Corporation ( CELG), AMGN, GILD, Regeneron Pharmaceuticals, Inc. ( REGN), Biogen Inc. ( BIIB) etc. It tracks the five-star Fidelity Biotechnology Portfolio Fund (MUTF: FBIOX ). FBT has shifted its strategy over the past year and has become broadly diversified with holdings in tools and services. Well known stocks include : Incyte Corporation ( INCY), Vertex Pharmaceuticals Incorporated ( VRTX), REGN, AMGN and diagnostic plays Myriad Genetics, Inc. ( MYGN), Qiagen N.V. ( QGEN). The technicals had rolled over into a downward channel but have recovered this week above the triple bottom for 2015 and at the SMA 200. Review the Rayno Biopharmaceutical Portfolio for new ideas and a comparison to the ETFs. For new investors and rebalancing healthcare portfolios we would favor complementary positions such as a fund FBIOX or IBB for core with XBI as a complement. Review our previous articles on Life Science ETFs which provides information on additional healthcare funds and ETF performance. Disclosure: I am/we are long GILD, FBIOX. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Additional disclosure: We use XBI long and short for trading and rebalancing portfolios. Share this article with a colleague